Page 130 - Haematologica July

1208
I. Criado et al.
Haematopoietic and Lymphoid Tissues.
4th ed. Lyon (France): IARC; 2017.
7. Rawstron AC, Shanafelt T, Lanasa MC, et al. Different biology and clinical outcome according to the absolute numbers of clonal B-cells in monoclonal B-cell lymphocytosis (MBL). Cytometry B Clin Cytom.
2010;78(Suppl. 1):19–23.
8. Rawstron AC, Bennett FL, O’Connor SJM,
et al. Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia. N Engl J Med. 2008;359(6):575–583.
9. Vardi A, Dagklis A, Scarfo L, et al. Immunogenetics shows that not all MBL are equal: the larger the clone, the more similar to CLL. Blood. 2013;121(22):4521–4528.
10. Fazi C, Scarfo L, Pecciarini L, et al. General population low-count CLL-like MBL per- sists over time without clinical progression, although carrying the same cytogenetic abnormalities of CLL. Blood. 2011;118(25):6618–6625.
11. Shim YK, Middleton DC, Caporaso NE, et al. Prevalence of monoclonal B-cell lym- phocytosis: a systematic review. Cytometry B Clin Cytom. 2010;78(Supp.l 1):10-18.
12. Nieto WG, Almeida J, Romero A, et al. Increased frequency (12%) of circulating chronic lymphocytic leukemia-like B-cell clones in healthy subjects using a highly sensitive multicolor flow cytometry approach. Blood. 2009;114(1):33–37.
13. Scarfo L, Fazi C, Ghia P. MBL versus CLL: how important is the distinction? Hematol Oncol Clin North Am. 2013;27(2):251–265.
14. Nieto WG, Teodosio C, López A, et al. Non-CLL-like monoclonal B-Cell lympho- cytosis in the general population: Prevalence and phenotypic/genetic charac- teristics. Cytometry B Clin Cytom. 2010;78(Suppl. 1):24–34.
15. Casabonne D, Almeida J, Nieto WG, et al. Common infectious agents and monoclon- al B-cell lymphocytosis: a cross-sectional epidemiological study among healthy adults. PLoS One. 2012;7(12):e52808.
16. Kalina T, Flores-Montero J, van der Velden VHJ, et al. EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols. Leukemia. 2012;26(9):1986–2010.
17. Flores-Montero J, Sanoja-Flores L, Paiva B, et al. Next Generation Flow for highly sen- sitive and standardized detection of mini- mal residual disease in multiple myeloma. Leukemia. 2017;31(10):2094–2103.
18. Quijano S, López A, Rasillo A, et al. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2008;74(3):139–149.
19. Efron B, Tibshirani R. Bootstrap methods for standard errors, confidence intervals, and other measures of statistial accuracy. Stat Sci. 1986;1(1):54-77.
20. Landgren O, Albitar M, Ma W, et al. B-cell clones as early markers for chronic lym- phocytic leukemia. N Engl J Med. 2009; 360(7):659-667.
21. Shanafelt TD, Ghia P, Lanasa MC, Landgren O, Rawstron AC. Monoclonal B- cell lymphocytosis (MBL): biology, natural history and clinical management.
Leukemia. 2010;24(3):512-520.
22. Shim YK, Vogt RF, Middleton D, et al.
Prevalence and natural history of monoclon- al and polyclonal B-cell lymphocytosis in a residential adult population. Cytometry B Clin Cytom. 2007;72(5):344-353.
23. Matos DM, Furtado FM, Falcao RP. Monoclonal B-cell lymphocytosis in indi- viduals from sporadic (non-familial) chron- ic lymphocytic leukemia families persists over time, but does not progress to chronic B-cell lymphoproliferative diseases. Rev Bras Hematol Hemoter. 2015;37(5):292- 295.
24. Greaves M, Maley CC. Clonal evolution in cancer. Nature. 2012;481(7381):306-313.
25. Henriques A, Rodriguez-Caballero A, Nieto WG, et al. Combined patterns of IGHV repertoire and cytogenetic/molecular alterations in monoclonal B lymphocytosis versus chronic lymphocytic leukemia. PLoS One. 2013;8(7):e67751.
26. Sanchez M-L, Almeida J, Gonzalez D, et al. Incidence and clinicobiologic characteris- tics of leukemic B-cell chronic lymphopro- liferative disorders with more than one B- cell clone. Blood. 2003;102(8):2994-3002.
27. Kern W, Bacher U, Schnittger S, et al. Flow cytometric identification of 76 patients with biclonal disease among 5523 patients with chronic lymphocytic leukaemia (B- CLL) and its genetic characterization. Br J Haematol. 2014;164(4):565-569.
28. Jacobs KB, Yeager M, Zhou W, et al. Detectable clonal mosaicism and its rela- tionship to aging and cancer. Nat Genet. 2012;44(6):651-658.
29. Machiela MJ, Zhou W, Caporaso N, et al. Mosaic 13q14 deletions in peripheral leukocytes of non-hematologic cancer cases and healthy controls. J Hum Genet. 2016;61(5):411-418.
30. Shanafelt TD, Kay NE, Rabe KG, et al. Brief report: natural history of individuals with clinically recognized monoclonal B-cell lymphocytosis compared with patients with Rai 0 chronic lymphocytic leukemia. J Clin Oncol. 2009;27(24):3959-3963.
31. Kern W, Bacher U, Haferlach C, et al. Monoclonal B-cell lymphocytosis is closely related to chronic lymphocytic leukaemia and may be better classified as early-stage CLL. Br J Haematol. 2012;157(1):86-96.
32. Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015; 126(4):454-462.
monoclonal B-cell lymphocytosis and ultra- stable chronic lymphocytic leukemia with low frequency of driver mutations. Haematologica. 2018 Feb 15. [Epub ahead of print].
37. Criado I, Muñoz-Criado S, Rodríguez- Caballero A, et al. Host virus and pneumo- coccus-specific immune responses in high- count monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia: impli- cations for disease progression. Haematologica. 2017;102(7):1238-1246.
38. te Raa GD, Tonino SH, Remmerswaal EBM, et al. Chronic lymphocytic leukemia specific T-cell subset alterations are clone- size dependent and not present in mono- clonal B lymphocytosis. Leuk Lymphoma. 2012;53(11):2321-2325.
39. Ghia P, Prato G, Stella S, Scielzo C, Geuna M, Caligaris-Cappio F. Age-dependent accumulation of monoclonal CD4+CD8+ double positive T lymphocytes in the peripheral blood of the elderly. Br J Haematol. 2007;139(5):780-790.
40. Purroy N, Wu CJ. Coevolution of leukemia and host immune cells in chronic lympho- cytic leukemia. Cold Spring Harb Perspect Med. 2017;7(4):a026740.
41. Os A, Bürgler S, Ribes AP, et al. Chronic lymphocytic leukemia cells are activated and proliferate in response to specific T helper cells. Cell Rep. 2013;4(3):566-77.
42. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012; 120(7):1412- 1421.
43. Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013; 121(9):1612-1621.
44. Morrison VA. Infectious complications of chronic lymphocytic leukaemia: pathogen- esis, spectrum of infection, preventive approaches. Best Pract Res Clin Haematol. 2010;23(1):145-153.
45. Moreira J, Rabe KG, Cerhan JR, et al. Infectious complications among individuals with clinical monoclonal B-cell lymphocy- tosis (MBL): a cohort study of newly diag- nosed cases compared to controls. Leukemia. 2013;27(1):136-141.
46. Forconi F, Moss P. Perturbation of the nor- mal immune system in patients with CLL. Blood. 2015;126(5):573-81.
47. Solomon BM, Chaffee KG, Moreira J, et al. Risk of non-hematologic cancer in individ- uals with high-count monoclonal B-cell lymphocytosis. Leukemia. 2016; 30(2):331-
33. Shanafelt TD, Kay NE, Rabe KG, et al.
Survival of patients with clinically identi-
fied monoclonal B-cell lymphocytosis
(MBL) relative to the age- and sex-matched
general population. Leukemia. 2012; 26(2):373-376. 336.
34. Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evo- lution in progression and relapse. Nature. 2015;526(7574):525-530.
35. Barrio S, Shanafelt TD, Ojha J, et al. Genomic characterization of high-count MBL cases indicates that early detection of driver mutations and subclonal expansion are predictors of adverse clinical outcome. Leukemia. 2017;31(1):170-176.
36. Agathangelidis A, Ljungström V, Scarfò L, et al. Highly similar genomic landscapes in
48. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associat- ed with adverse outcomes. N Engl J Med. 2014;371(26):2488-2498.
49. Genovese G, Kahler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-2487.
haematologica | 2018; 103(7)